不同剂量阿托伐他汀对2型糖尿病患者纤溶活性的影响

目的研究不同剂量阿托伐他汀对2型糖尿病患者纤溶活性的影响。方法用酶联免疫吸附法(ELISA)测定2型糖尿病患者外周血中血浆纤溶酶原激活剂(t-PA)及其血浆纤溶酶原激活剂抑制物-1(PAI-1)的水平,并比较不同剂量阿托伐他汀对它们的影响。结果10 mg和20 mg阿托伐他汀治疗前后总胆固醇(TC)、PAI-1均有显著下降(P<0.05)、t-PA水平显著上升(P<0.05),20 mg组治疗后TC、t-PA及PAI-1均较10 mg组差异有统计学意义(P<0.05)。结论阿托伐他汀对2型糖尿病患者纤溶活性有积极作用,且在一定范围内随着剂量的增加而加强,同时具有良好的安全性。

Effect of different dosages of Atorvastatin on fibrinolytic activity in patients with type 2 diabetes mellitus

Objectives To investigate the effect of different dosage （ 10mg/d or 20mg/d） of Atorvastatin on fibrinolytic activity in patients with type 2 diabetes mellitus. Methods The levels of plasma t-PA and PAI-1 in pa- tients with type 2 diabetes mellitus were measured by ELISA. Results Compared to the basal value, the levels of plasma TC and PAI-1 decreased significantly ,but the plasma t-PA was increased markedly both in 10mg dosage group and 20mg dosage group after the treatment of Atorvastatin, P 〈 0.05 ; the differences were significant in plasma TC, PAI-1 and t-PA levels between two dosage groups after the treatment of Atorvastatin, P 〈 0.05 ; no visble statistical differences of CK,GGT,GOT were found between two groups. Conclusion Atorvastatin has active effect on fibfinolytic activity in patients with type 2 diabetes mellitus with good safely, with good safety, and the effect is dose-depend- ent within a range of dosage.